• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Psychemedics Corporation (Amendment)

    2/14/23 5:00:48 PM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email
    SC 13G/A 1 sc13ga_021423.htm FORM SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    Psychemedics Corporation

    (Name of Issuer)

     

    Common Stock - $.005 Par Value

     

    744375205

    (CUSIP Number)

     

     

      December 31, 2022  

    Date of Event which requires filing of this statement

     

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

     

    ☐       Rule 13d-1(b)

     

    ☐       Rule 13d-1(c)

     

    ☒       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 744375205Page 2 of 5 pages

     

    SCHEDULE 13G

    Amendment No. 2

     

     

    1) Names of Reporting Persons; S.S. or I.R.S. Identification Nos. of Above Persons  
         
      Raymond C. Kubacki  
         
    2) Check the Appropriate Box if a Member of a Group (See Instructions)  
         
      (a)    
         
      (b)    

     

    3) SEC Use Only    

     

    4)Citizenship or Place of Organization U.S.A.  

     

     

    Number of Shares 5) Sole Voting Power 379,712  
    Beneficially Owned        
    By Each Reporting 6) Shared Voting Power 0  
    Person With        
      7) Sole Dispositive Power 379,712  
             
      8) Shared Dispositive Power 0  

     

    9) Aggregate Amount Beneficially Owned by Each Reporting Person  
         
      379,712  

     

    10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  
         
         

     

     

    11) Percent of Class Represented by Amount in Row (9)  
         
      6.5%  

     

     

    12) Type of Reporting Person (See Instructions)  
         
      IN  

     

     
    CUSIP No. 744375205Page 3 of 5 pages

     

    SECURITIES AND EXCHANGE COMMISSION

    SCHEDULE 13G

    Amendment No. 2

     

     

    1) (a) Name of Issuer: Psychemedics Corporation
         
      (b) Address of Issuer's Principal Executive Offices:
         
        289 Great Road
        Suite 200
        Acton, Massachusetts 01720
         
    Item 2 (a) Name of Person Filing: Raymond C. Kubacki
         
      (b) Address of Principal Business Office or, if none, Residence:
         
        289 Great Road
        Suite 200
        Acton, Massachusetts 01720
         
      (c) Citizenship: USA
         
      (d) Title of Class of Securities: Common Stock, $.005 par value
         
      (e) CUSIP NUMBER: 744375205
         
    Item 3   If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [   ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
      (b) [   ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) [   ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) [   ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
      (e) [   ] An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
      (f) [   ] An employee benefit plan or endowment fund in accordance with §240.13d1(b)(1)(ii)(F).
      (g) [   ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
      (h) [   ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) [   ] A church plan that is excluded from the definition if an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [   ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     
    CUSIP No. 744375205Page 4 of 5 pages

     

     

    Item 4 (a) Amount Beneficially Owned:                                                                                                                                                               379,712  
           
      (b) Percent of Class:                                                                                                                                                                                         6.5%  
           
      (c) Number of Shares as to which such person has:  

     

      (i) sole power to direct the vote 379,712  
             
      (ii) shared power to vote or to direct the vote 0  
             
      (iii) sole power to dispose or to direct the disposition of 379,712  
             
      (iv) shared power to dispose or to direct the disposition of 0  

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    Not Applicable

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person:

     

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

     

    Not Applicable

     

    Item 8Identification and Classification of Members of the Group:

     

    Not Applicable

     

    Item 9Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10Certification

     

    Not Applicable

     

     
    CUSIP No. 744375205Page 5 of 5 pages

    After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

     

     

      February 14, 2023
      Date
       
       
      /s/ Raymond C. Kubacki
      Signature
       
       
      Raymond C. Kubacki
      Name/Title
       
       

     

     

     

     

     

     

     

     

     

     

     

    Get the next $PMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights

      DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench

      3/3/25 9:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Announces Reverse and Forward Stock Split

      DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

      12/2/24 8:10:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of Stockholders

      DALLAS, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing, reminds its stockholders to vote ahead of the Company's upcoming annual meeting of stockholders scheduled for November 25, 2024. Each stockholder's vote is important. The Company's Board of Directors recommends that stockholders vote "FOR" each proposal at the annual meeting. Instructions for voting your shares are set forth below. The record date for the annual meeting is October 8, 2024. If you have previously voted your shares and do not wish to change your vote, you do not need to take any action. If you have already voted or given your proxy and wish to change your vote,

      11/18/24 8:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 5:15:34 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by Psychemedics Corporation

      15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

      1/2/25 4:10:54 PM ET
      $PMD
      Medical Specialities
      Health Care
    • SEC Form 25 filed by Psychemedics Corporation

      25 - PSYCHEMEDICS CORP (0000806517) (Filer)

      12/13/24 8:00:57 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

      SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/10/24 4:46:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/12/24 5:15:40 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

      SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/6/24 9:18:20 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/5/24 6:04:48 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

      ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

      11/27/23 9:00:00 AM ET
      $NBSE
      $PMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Psychemedics Corporation Reports Third Quarter 2023 Financial Results

      ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

      11/9/23 5:00:59 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

      ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

      9/21/23 5:00:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/5/24 6:05:08 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Financials

    Live finance-specific insights

    See more
    • Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

      ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

      10/27/23 11:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports Second Quarter 2023 Financial Results

      ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

      8/11/23 5:10:31 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

      ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

      5/9/23 5:30:00 PM ET
      $PMD
      Medical Specialities
      Health Care